- Path:
-
Volume
Files
File
Description
Size/Format
Periodical
- Title:
- Journal of laboratory medicine
- Publication:
-
Berlin: De Gruyter
- Note:
- Gesehen am 23.07.2020
- Open Access
- Namensnennung 4.0 International
- 355!URL-Ä.(18-05-20)
- ISSN:
- 2567-9449
- ZDB-ID:
-
2909042-8
- VÖBB-Katalog:
- 35278181
- Previous Title:
- Laboratoriumsmedizin
- Keywords:
- Zeitschrift
- Classification:
- Medizin
- Collection:
- Medizin
- Copyright:
- Rights reserved
- Accessibility:
- Free Access
- Title:
- Journal of laboratory medicine
- Publication:
-
Berlin: De Gruyter
- Note:
- Gesehen am 23.07.2020
- Open Access
- Namensnennung 4.0 International
- 355!URL-Ä.(18-05-20)
- ISSN:
- 2567-9449
- ZDB-ID:
-
2909042-8
- VÖBB-Katalog:
- 35278181
- Previous Title:
- Laboratoriumsmedizin
- Keywords:
- Zeitschrift
- Classification:
- Medizin
- Collection:
- Medizin
- Copyright:
- Rights reserved
- Accessibility:
- Free Access
Article
- Title:
- Diagnostic value of anti-hexokinase 1 and anti-kelch-like 12 antibodies in primary biliary cholangitis patients
- Publication:
-
Berlin: De Gruyter, 2024
- Language:
- English
- Information:
- Objectives: Anti-mitochondrial antibody (AMA) is not always present in patients with primary biliary cholangitis (PBC). We aimed to determine the additional value of anti-hexokinase 1 (anti-HK1) and anti-kelch-like 12 (anti-KLHL12) antibody in PBC and analyzed the biochemical and immunological parameters of 212 subjects, including PBC patients and healthy controls. Methods: Serum anti-gp210 and sp100 antibodies were determined by an immunoblotting test (IBT). Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate anti-HK1 and anti-KLHL12. The diagnostic value of anti-HK1 and anti-KLHL12 to PBC was analyzed by constructing a receiver operating characteristic (ROC) curve. Results: ROC analyses didn’t show a very good performance of serum anti-HK1 for PBC diagnosis; the AUC was 0.664 with a sensitivity of 53.3 % and a specificity of 79.2 %. Regarding anti-KLHL12, ROC analysis yielded an AUC of 0.626, with a sensitivity of 45.7 % and a specificity of 93.8 %. For AMA-negative PBC patients, the AUC increased to 0.790 for KLHL12, and 0.708 for HK1. AMA combined with anti-HK1 or anti-KLHL12 antibody significantly improved the diagnostic sensitivity of PBC from 82 to about 95 %, respectively. In AMA-negative PBC patients, the sensitivities for anti-HK1 (62.50 %) and anti-KLHL12 (75 %) antibodies were higher than for anti-gp210 (37.5 %) and anti-sp100 antibody (43.75 %). When these four antibodies were combined, the overall sensitivity increased to 87.5 %. Conclusions: The determination of anti-HK1 and anti-KLHL12 facilitates the diagnosis of PBC, particularly in AMA-negative patients. Adding anti-HK1 and anti-KLHL12 antibodies to clinical detection enables early diagnosis and timely treatment, potentially improving patient prognosis.
- Scope:
- Online-Ressource
- Note:
- Open Access
- Archivierung/Langzeitarchivierung gewährleistet
- Keywords:
- anti-hexokinase 1 antibody ; anti-kelch-like 12 antibody ; diagnosis ; primary biliary cholangitis
- Copyright:
- CC BY
- Accessibility:
- Free Access
- Title:
- Diagnostic value of anti-hexokinase 1 and anti-kelch-like 12 antibodies in primary biliary cholangitis patients
- Publication:
-
Berlin: De Gruyter, 2024
- Language:
- English
- Information:
- Objectives: Anti-mitochondrial antibody (AMA) is not always present in patients with primary biliary cholangitis (PBC). We aimed to determine the additional value of anti-hexokinase 1 (anti-HK1) and anti-kelch-like 12 (anti-KLHL12) antibody in PBC and analyzed the biochemical and immunological parameters of 212 subjects, including PBC patients and healthy controls. Methods: Serum anti-gp210 and sp100 antibodies were determined by an immunoblotting test (IBT). Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate anti-HK1 and anti-KLHL12. The diagnostic value of anti-HK1 and anti-KLHL12 to PBC was analyzed by constructing a receiver operating characteristic (ROC) curve. Results: ROC analyses didn’t show a very good performance of serum anti-HK1 for PBC diagnosis; the AUC was 0.664 with a sensitivity of 53.3 % and a specificity of 79.2 %. Regarding anti-KLHL12, ROC analysis yielded an AUC of 0.626, with a sensitivity of 45.7 % and a specificity of 93.8 %. For AMA-negative PBC patients, the AUC increased to 0.790 for KLHL12, and 0.708 for HK1. AMA combined with anti-HK1 or anti-KLHL12 antibody significantly improved the diagnostic sensitivity of PBC from 82 to about 95 %, respectively. In AMA-negative PBC patients, the sensitivities for anti-HK1 (62.50 %) and anti-KLHL12 (75 %) antibodies were higher than for anti-gp210 (37.5 %) and anti-sp100 antibody (43.75 %). When these four antibodies were combined, the overall sensitivity increased to 87.5 %. Conclusions: The determination of anti-HK1 and anti-KLHL12 facilitates the diagnosis of PBC, particularly in AMA-negative patients. Adding anti-HK1 and anti-KLHL12 antibodies to clinical detection enables early diagnosis and timely treatment, potentially improving patient prognosis.
- Scope:
- Online-Ressource
- Note:
- Open Access
- Archivierung/Langzeitarchivierung gewährleistet
- Keywords:
- anti-hexokinase 1 antibody ; anti-kelch-like 12 antibody ; diagnosis ; primary biliary cholangitis
- Copyright:
- CC BY
- Accessibility:
- Free Access
